RxDoctor Payments Data

Vanessa Lopez Beauchamp, MD

Ophthalmology · San Juan, PRNPI 1760683940

Payments from drug & device makers

$1,216in general payments, 2019–2025

Across 33 payments — averaging $36.84 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$407
  • Alcon Puerto Rico Inc$294
  • Oculus, Inc.$140
  • Bausch & Lomb Americas Inc.$118
  • Rxsight Inc$105
  • Dompe US, Inc.$54
  • plus $97 from 3 others

What the payments were for

  • Food & beverage$1,216100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,216 in reported general payments places this provider in the 65th percentile of 214 ophthalmology providers in Puerto Rico.

See all ophthalmology providers in Puerto Rico

Medicare billing

Part B allowed, 2024
$38,617
Medicare patients
97
Services billed
555

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RestasisCyclosporine94$60,671
Prednisolone Acetate1,421$56,867
Alphagan PBrimonidine Tartrate177$40,185
LumiganBimatoprost137$40,151
Cyclosporine77$17,889
Brimonidine Tartrate125$15,428
Ketorolac Tromethamine348$12,175
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol55$11,047
CombiganBrimonidine Tartrate/Timolol45$9,957
Ofloxacin378$8,729
Fluorometholone101$6,906
Loteprednol Etabonate46$6,645
AzoptBrinzolamide16$5,973
MoxifloxacinMoxifloxacin Hcl171$4,267
Travoprost31$4,259

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRestasis, Alphagan P, Lumigan, Combigan$407$150,964453 claims
Bausch & Lomb, A Division Of Bausch Health US, LLCLoteprednol Etabonate, Lotemax$15$10,78462 claims
AlconAzopt, Simbrinza$52$9,76534 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 214 ophthalmology providers in Puerto Rico.

Other ophthalmology in San Juan

See the full list for Puerto Rico

Where these figures come from

Is this you, or does something look wrong? →